Shape Pharmaceuticals, Inc. is a project-focused company founded by James Bradner, M.D., and Ralph Mazitschek, Ph.D., and funded by HealthCare Ventures. SHP-141, the first topical HDAC being prepared for clinical trials, has promising pre-clinical data supporting potential use in patients with CTCL. The development of SHP-141 is being supported through a business alliance with the Leukemia & Lymphoma Society, which is providing funding of up to $3.3 million. |
07.27.2010The Leukemia & Lymphoma Society® and Shape Pharmaceuticals Partner to Advance Clinical Development of Novel, Topical Therapy for Cutaneous T-Cell Lymphoma |